anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
OBJECTIVE: To compare neonatal outcomes following URS, stent, or PCN in pregnant women presenting with suspected renal colic.
METHODS: Women undergoing a procedure for suspected renal colic during pregnancy at a large multi-center institution between 2008 and 2022 were retrospectively reviewed and categorized by initial intervention. Neonatal outcomes were recorded and linked to maternal and obstetric data. Groups were compared by a Kruskal-Wallis, ANOVA, or Fisher's Exact test, followed by pairwise post-hoc testing as appropriate (α = 0.05). Multivariate analyses were also conducted.
RESULTS: 95 patients were analyzed, of whom 32 were managed with PCN, 47 with stent, and 16 with URS. Maternal baseline characteristics were similar between groups, except for lower gravidity and parity in the stent group. Rates of premature delivery did not differ, but gestational age at delivery was lower in the PCN group versus the stent and URS groups (p = 0.006 and p = 0.025, respectively). Neonatal Intensive Care Unit (NICU) admission rates were higher in the PCN group versus the stent and URS groups (p = 0.006 and 0.036, respectively). Respiratory distress syndrome significantly differed between groups (p = 0.041). Neonatal birth weight, Apgar scores, and other complications did not significantly differ.
CONCLUSION: This study demonstrated higher rates of NICU admissions and lower gestational age at delivery for neonates born to mothers managed with PCN compared to stent and URS. Larger multi-institutional studies are warranted to further explore these associations.
PURPOSE:To obtain a thromboembolic agent consisting of an aqueous suspension containing thrombin, heavy metal and polyethylene glycol and useful for treatment for aneurysm, vascular malformation, hemostasis and tumor. CONSTITUTION:The objective thromboembolic agent consisting of an aqueous suspension containing thrombin, heavy metal (e.g. gold, silver, thorium, etc.) and polyethylene glycol (preferably having 10000-100000 molecular weight). The agent is prepared by e.g. boiling 0.01-50% tetrachloroauric (III) acid, adding 0.1-5.0% citric acid thereto, quickly mixing these ingredients and cooling the mixture to ambient temperature, adding 0.1-10% polyethylene glycol (PEG) thereto, controlling pH of the mixture to 5.9 by acetic acid to prepare gold colloid, adding thrombin and PEG to the gold colloid, centrifuging the mixture, re-floating the resultant precipitate in phosphoric acid buffer solution (having pH7.2) and adding thrombin thereto.
Little is known of the host and the bacteria response in vivo in patients with Lyme disease. In an attempt to better understand the pathology of erythema migrans (EM), we will use a variety of techniques to characterize patterns in skin biopsies from individuals with a diagnosis of EM and compared those to the patterns seen in biopsies from unaffected individuals. Biopsies from patients may also be evaluated for B. burgdorferi. Patients diagnosed with erythema migrans will have between 2 and 4 punch skin biopsies of affected area, and will return for 4 follow up visits in the course of a year. Therapy for Lyme disease will be offered. Healthy volunteers will have a screening visit, a visit for the skin biopsies and a follow up visit. Patients and healthy volunteers will be compensated for their time and inconvenience.
The invention provides methods and materials for treating the effects of nicotine. In particular, the invention provides methods that involve administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist typically is administered in an amount effective to diminish or abolish the effects that nicotine has on the treated mammal. NTR agonists that can be used in methods of the invention include neurotensin (NT) polypeptide analogs such as NT69L. The invention also provides compositions containing an NTR agonist in combination with other agents used to help overcome nicotine effects such as sensitization and dependence. The compositions provided herein can be used to treat the effects of nicotine, including hyperactivity, hypothermia, respiratory distress, and hypertension.
Two age groups (children 2 to \<12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
This group includes persons 15 years and older who are started on PrEP at the STI clinic. Participants in this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
This study is a single-center, randomized, open-label, 13-week, 2-period crossover clinical trial. Subjects will complete each of the following (unless they withdraw from the trial): (1) a one-week baseline period during which the subject completes pain diaries and remains on stable dosages of their existing pain medications; (2) immediate-release (IR) oxycodone 5 mg 3-4 pills every four hours; (3) extended-release (ER) oxycodone 40 mg 1 pill every 12 hours and IR-oxycodone 5 mg 1-2 pills every six hours. Subjects will be randomized to one of two treatment sequences (ER-oxycodone first then IR-oxycodone or vice verse). It is expected that this trial will take approximately 2 years to complete.

Crossover periods. Each of the two treatment periods will be 6 weeks in duration, which will allow ample time to assess pain relief, adverse effects, treatment satisfaction, and impact of treatment on health-related quality of life. There will be no need for a titration period at the beginning of either period or for a washout period before the second period because oxycodone at the same dosages will be administered in both periods. At each visit, subjects will be given sufficient medication to sustain them until at least the following visit.
PURPOSE:The titled pharmaceutical, prepared by laminating a chemical storage layer on a backing member, and further laminating a chemical diffusion controlling layer consisting of an airpermeable porous layer having the chemical permeability on the above-mentioned chemical storage layer in order, and capable of releasing the chemical at a controlled rate for a long term. CONSTITUTION:A pharmaceutical for prolonged release of a chemical prepared by laminating a chemical storage layer 2 consisting of a chemical-permeable rsin, e.g. a silicone resin or polyurethane, and the chemical contained therein on a backing member 1 consisting of preferably a flexible chemical-impermeable sheet material, and further laminating a chemical diffusion controlling layer 3 consisting of an air-permeable porous layer having the chemical permeability on the above-mentioned chemical storage layer 2 in order. The above-mentioned chemical diffusion controlling layer 3 may be constituted of a porous resin layer of the chemical-permeable resin, but preferably a fiber assembly consisting of the chemical-permeable resin, e.g. a knitted or woven fabric or nonwoven fabric. In the latter case, KABURE of the skin due to the perspiration will not be caused even in the application for a long term.
The purpose of this study is to improve pain management for patients having spine fusion surgery. This aim will be achieved by evaluating how well liposomal bupivacaine (LB), an FDA approved numbing medication that can provide pain relief for up to 72 hours after surgery, works when used as a single dose in a regional block known as Erector Spinae Plane block (ESPB). ESPB is a regional anesthesia technique used to control pain after surgery by injecting numbing medication around the patient's back bones on both sides. The study will compare how well LB in ESPB works compared to the standard practice procedure, which involves administering the traditional numbing medication (bupivacaine) through the ESPB. These two medications will be evaluated in reducing postoperative opioid medication need to control postoperative pain, as the primary goal. This study seeks to understand whether an ESP block either with bupivacaine and stabilizing agents or using liposomal bupivacaine, reduces the total amount of opioid medication used postoperatively, reduces pain scores, and leads to better patient reported outcome scores, patient satisfaction, and reduced recovery time in the PACU. Should the investigator find that liposomal bupivacaine is not superior to bupivacaine with stabilizing agents, this information would prove useful in regards to analgesic options for this patient population and could lead to a substantial cost savings.
Objective To explore the predictive value of radiomics nomogram combining with CT radiomics features and clinical features for postoperative early recurrence in patients with BRAF-mutant colorectal cancer. Methods A total of 220 patients with surgically and pathologically confirmed BRAF-mutant colorectal cancer from 2 institutions were retrospectively included. All patients from institution 1 were randomized at a 7:3 ratio into a training cohort (n = 108) and an internal validation cohort (n = 45), and patients from institution 2 were used as an external validation cohort (n = 67). The association between the radiomics features and early recurrence was assessed in the training cohort and verified in the validation cohort. Furthermore, the performance of the radiomics nomogram was evaluated by combining the rad-score and clinical risk factors. The predictive performance was evaluated by receiver operating characteristic curve analysis, calibration curve analysis, and decision curve analysis. Results The dierenees in the Lymphocyte/monocyte ratio (LMR) and Peripheral nerve infiltration (PNI) were statistically significant between the early recurrence in BRAF-mutant colorectal cancer groups and the early non-recurrence in BRAF-mutant colorectal cancer groups (P < 0.05); The two groups showed no significant differenee in clinical parameters including age, sex, and biochemistry serum markers (P > 0.05). Comparing with the pure radiomics or clinical data, combined models can be seen that the addition of LMR and PNI further improveed the predictive efficiency of the model. The rad-score based on LR, generated by 4 selected radiomics features, demonstrated a favorable ability to predict early recurrence in both the training (AUC 0.81), internal validation (AUC 0.73), external validation (AUC 0.63) cohorts. Subsequently, integrating two independent predictors into a nomogram exhibited more favorable discriminatory performance, with the AUC improved to 0.88 and 0.81 in both cohorts. Conclusions The proposed CT-based radiomics signature is associated with early recurrence among the patients with BRAF-mutant colorectal cancer. The present study also proposes a combined model can potentially be applied in the individual preoperative prediction of early recurrence in patients with BRAF-mutant colorectal cancer. Advances in knowledge CT-based radiomics showed satisfactory diagnostic significance for early recurrence in patients with BRAF-mutant colorectal cancer. Key baseline clinical characteristics were associated with early recurrence in patients with BRAF-mutant colorectal cancer. The combined model may be applied in the individual preoperative prediction of early recurrence in patients with BRAF-mutant colorectal cancer.
This a prospective single arm study enrolling patients with bone metastases from breast cancer who have been on opioid therapy for bone pain for at least 4 weeks. All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks). For patients who have side effects secondary to Sydnros, the dose will be decreased. Side effect assessment will be done by the research team 2 days after making the dose adjustment. If subject continues to have side effects, dose will be held until resolution of symptoms. If the study medicine is held for more than a week continuously, they will be taken off the study. In addition, they will have baseline blood and urine collected for biomarkers and also complete study related questionnaires (for secondary end points). They are also provided an opioid drug diary which they will take home during visit 1 to record their opioid pain medication use. Research staff will be calling patients on a weekly basis to reinforce opioid drug diary, assess for Syndros side effect, and adjust dose of Syndros. At the end of 8 weeks blood and urine is collected again and they will complete the study questionnaires.
A system for mounting a needle shield to a syringe. The system includes a syringe nest and a gripper having a gripping position and a release position. The gripper is movable between an aligned position and a spaced position. A shaker has a shaker axis that is generally coaxial with the syringe axis. The shaker is movable along the shaker axis. An inspection camera is positioned proximate the syringe axis and defines a line of sight. The syringe nest, gripper, shaker and cap plunger are generally aligned along the syringe axis in a placing configuration wherein the gripper is in the gripping position holding the needle shield. The gripper is in the spaced position and the distal end of the cap plunger is in engagement with the needle shield in a final cap mounting configuration.
The arterial catheterizations were usually performed by anesthesiologists in operation rooms and intensive care units for many reasons such as blood pressure monitoring and gas sampling. The choice of radial artery is because of its anatomic advantages. However some patients related features can cause difficulties in catheterization. The use of ultrasounography (USG) guidance raises the rate of success and decreases the complications. Coordination skills between hand, eye, procedure area and screen are essential for the USG-guided catheterization. Smarth glasses, project the USG image in real-time directly in front of the practitioner's eyes and thus allows the practitioner to simultaneously view the screen and the procedure area. The primer aim of this study is to evaluate the success rate and anesthesiologist's satisfaction between two practitioners with different levels of experience in radial artery catheterization with smart glasses USG. The secondary aims are to evaluate the cannulation time and complications between groups.

120 patients \>18 years who would be undergone elective elective surgery with an indication for radial artery catheterization between August 2022 and December 2022 were included to the prospective, randomised, single centre study. Patients underwent radial artery catheterization for any reason in the last one month, and with contraindications for catheterization were excluded. Patients were divided randomly into two groups (Group I: patients underwent radial artery catheterization using standart USG, and Group II: patients underwent radial artery catheterization using smart glasses integrated UGG). The catheterization was performed by two anesthetists with different experience. The subcutaneous distance, radial artery depth and diameter in short axis, cannulation time and ergonomic satisfaction of the practitioners were recorded. The program SPSS 11.5 was used to analyze data.
VYVANSE has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. VYVANSE can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of lisdexamfetamine, a prodrug of amphetamine, may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Studies of VYVANSE in Drug Abusers

A randomized, double-blind, placebo-control, cross-over, abuse liability study in 38 patients with a history of drug abuse was conducted with single-doses of 50, 100, or 150 mg of VYVANSE, 40 mg of immediate-release d-amphetamine sulphate (a controlled II substance), and 200 mg of diethylpropion hydrochloride (a controlled IV substance). VYVANSE 100 mg produced significantly less "Drug Liking Effects" as measured by the Drug Rating Questionnaire-Subject score, compared to d-amphetamine 40 mg; and 150 mg of VYVANSE demonstrated similar "Drug-Liking Effects" compared to 40 mg of d-amphetamine and 200 mg of diethylpropion.

Intravenous administration of 50 mg lisdexamfetamine dimesylate to individuals with a history of drug abuse produced positive subjective responses on scales measuring "Drug Liking", "Euphoria", "Amphetamine Effects", and "Benzedrine Effects" that were greater than placebo but less than those produced by an equivalent dose (20 mg) of intravenous d-amphetamine.
The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs. The invention also provides compositions, including pharmaceutical compositions, comprising any of the aforementioned EphA2-BiTEs, polynucleotides or vectors either alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are methods of screening for said EphA2-BiTEs and kits comprising any of the aforementioned compositions and diagnostic reagents.
PURPOSE:An oily beautiful and white cosmetic stabilized and easily usable, prepared by dissolving an ascorbic acid higher fatty acid ester in an oil base in the presence of a specific trialkyl phosphate. CONSTITUTION:One part by wt. of an ascorbic acid higher fatty acid ester e.g. ascorbic acid dipalmitate, is dissolved with 0.5-100 parts by wt. of a trialkyl phosphate, e.g. triethyl phosphate, of the formula (R is 2-8C alkyl group) in a liquid oil base, e.g. isopropyl palmitate, to give the desired only beautiful and white cosmetic, which is a substantially transparent liquid.
The present invention relates to a method for producing the fruit juice of germinant unpolished rice and ganoderma lucidum and product thereof, and Korean ganoderma lucidum is used as culture. The pulp of the germinant unpolished rice is mainly used, and malt wort and the pulp of soybean sprout are used as the nutrient media components of the submerged fermentation of the ganoderma lucidum. After the culture is cultivated in enlarged way by a slant, a first level shake bottle and a second level seed tank, the submerged fermentation cultivation of the culture in a 100L fermentation tank is carried out for 3-4 days. After fermentation liquid is prepared with apple juice, white grape juice and orange juice, the fruit juice of germinant unpolished rice and ganoderma lucidum is produced through the working procedures of uniformly shaking, degassing, sterilizing, cooling, etc. The method has the advantages of high industrialization degree, cheap and simple nutrient media raw materials, low production cost and good finished product mouth feel and simultaneously comprises bioactivity components, such as ganoderma lucidum polyoses, gamma-aminobutanoic acid, etc. The fruit juice of germinant unpolished rice and ganoderma lucidum is the drink with unambiguous nutrition health-caring function.
The invention relates to biotechnology and pharmacology, in particular to a method for producing a Fortelyzin preparation which has fibrinolytic properties, and to the use thereof for treating myocardial infarction. A method is proposed which consists in thawing a supernatant comprising a recombinant protein with a staphylokinase amino acid sequence (RPSPH). The RPSPH is isolated and chromatographically purified on CM Sepharose. The RPSPH is chromatographically purified on DEAE Sepharose. The RPSPH is then transferred into a 0.3% NaCl solution. The substance is sterilized, packaged, subjected to lyophilic drying and marked. 20 litres of water for injection are introduced into a reactor containing a mixer and having a working volume of 160 l, followed by 150 g of the substance and water for injection in a quantity of 10 l, the reactor mixer is switched on (mixing speed 80 rpm) and mixing is carried out for 15 min., after which the reactor mixer is switched off, a sample is taken and the pH of the solution produced is recorded - the pH must be within a range of 5.5 to 7.5. The solution is subjected to sterilizing filtration, and vials are filled and provisionally sealed. The preparation is then subjected to lyophilic drying and the vials are sealed definitively. The finished product is marked and packaged. It is proposed to use the Fortelyzin preparation for treating myocardial infarction by intravenous administration in a dose of 15 mg (2 235 000 IU), wherein, before the preparation is administered, the contents of a 5 mg (745 000 IU) vial are diluted in 5 ml of a 0.9% sodium chloride solution, and the preparation is administered either as two boluses simultaneously, i.e. 10 mg (1 490 000 IU), and the remaining 5 mg (745 000 IU) after 30 minutes, or first of all 10 mg (1 490 000 IU) in bolus form, and the remaining 5 mg (745 000 IU) by intravenous infusion in 50 ml of a 0.9% sodium chloride solution over 30 min. The invention expands the range of drugs having fibrinolytic properties.